title: Investigating Synthetic Oligonucleotide Targeting of Mir31 in Duchenne Muscular Dystrophy.
abstract: Exon-skipping via synthetic antisense oligonucleotides represents one of the most promising potential therapies for Duchenne muscular dystrophy (DMD), yet this approach is highly sequence-specific and thus each oligonucleotide is of benefit to only a subset of patients. The discovery that dystrophin mRNA is subject to translational suppression by the microRNA miR31, and that miR31 is elevated in the muscle of DMD patients, raises the possibility that the same oligonucleotide chemistries employed for exon skipping could be directed toward relieving this translational block. This approach would act synergistically with exon skipping where possible, but by targeting the 3'UTR it would further be of benefit to the many DMD patients who express low levels of in-frame transcript. We here present investigations into the feasibility of combining exon skipping with several different strategies for miR31-modulation, using both in vitro models and the mdx mouse (the classical animal model of DMD), and monitoring effects on dystrophin at the transcriptional and translational level. We show that despite promising results from our cell culture model, our in vivo data failed to demonstrate similarly reproducible enhancement of dystrophin translation, suggesting that miR31-modulation may not be practical under current oligonucleotide approaches. Possible explanations for this disappointing outcome are discussed, along with suggestions for future investigations.
authors.affiliation: Department of Comparative and Biomedical Sciences, The Royal Veterinary College, London, UK.
authors.forename: John Cw
authors.initials: JC
authors.lastname: Hildyard
authors.affiliation: Department of Comparative and Biomedical Sciences, The Royal Veterinary College, London, UK.
authors.forename: Dominic J
authors.initials: DJ
authors.lastname: Wells